Clinical trial
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
NCT00126490 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00126490 |
|---|---|
| Title | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer |
| Official title | Phase 2 Trial of Sequential Bevacizumab Then Subcutaneous Interleukin-2 in Metastatic Renal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer |
| Intervention type | Biological, Other |
| Interventions | Aldesleukin, Bevacizumab, Laboratory Biomarker Analysis |
| Enrollment | 19 |
| Start date | Mar 1, 2005 |
| Primary completion | Jun 1, 2012 |
| Completion | Aug 1, 2013 |
| First posted | Aug 4, 2005 |
| Last update posted | Jun 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: